Evommune, Inc.
Income Statement
| Line Item | FY2025 | FY2024 |
|---|---|---|
| Revenue | $13.0M | $7.0M |
| Cost of Revenue | — | — |
| Gross Profit | — | — |
| Gross Margin | — | — |
| Operating Expenses | ||
| Research & Development | $74.0M | $64.2M |
| SG&A Expense | $20.0M | $12.8M |
| Operating Income | $-81.1M | $-70.0M |
| Operating Margin | -623.6% | -1,000.2% |
| Interest Expense | — | — |
| Pretax Income | $-68.9M | $-68.3M |
| Income Tax Expense | $0 | $0 |
| Net Income | $-68.9M | $-66.8M |
| Net Margin | -529.8% | -954.4% |
| EPS (Basic) | $-11.22 | $-45.29 |
| EPS (Diluted) | $-11.22 | $-45.29 |
| Shares Outstanding (Basic) | 6.1M | 1.5M |
| Shares Outstanding (Diluted) | 6.1M | 1.5M |
| Dividends Per Share | — | — |